Scrutiny of the CBD market appears to be growing at the US Food and Drug Administration (FDA), which this week reprimanded a further 15 companies for selling CBD products as drugs and also updated its advice to consumers on potential dangers ...
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.